Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447240 | 0.94 | HTT (0.60) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL31075460 | 0.94 | HTT (0.60) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL396813 | 0.83 | HTT (0.62) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL446463 | 0.82 | HTT (0.57) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL30038601 | 0.81 | TDP1 (0.58) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL1494244 | 0.81 | TDP1 (0.58) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL1012155 | 0.78 | HTT (0.45) | HTTTDP1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL2815081 | 0.77 | HTT (0.54) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL28131718 | 0.75 | TDP1 (0.51) | HTTTDP1PKMLMNASMN1; SMN2 | |
| SCHEMBL21398693 | 0.74 | MEN1 (0.53) | HTTTDP1PKMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | HTT 4164/4885TDP1 4665/4885PKM 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.